Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid in Capital	Accumulated Other Comprehensive Income / (Loss)	Accumulated Deficit
Beginning balance at Dec. 31, 2020	$ 172,262	$ 29	$ 318,574	$ 313	$ (146,654)
Beginning balance, shares at Dec. 31, 2020		29,543,222
Exercise of stock options	6,808	$ 1	6,807
Exercise of stock options, shares		531,190
Stock based compensation	29,853		29,853
Foreign currency translation adjustments	20			20
Unrealized gain (loss) on available for sale investments	(412)			(412)
Net loss	(89,945)				(89,945)
Ending balance at Dec. 31, 2021	118,586	$ 30	355,234	(79)	(236,599)
Ending balance, shares at Dec. 31, 2021		30,074,412
Issuance of common stock , net of issuance costs	608		608
Issuance of common stock , net of issuance costs, shares		51,769
Issuance of common stock on exercise of stock options and vesting of restricted stock units	148		148
Issuance of common stock on exercise of stock options and vesting of restricted stock units, shares		490,299
Stock based compensation	16,618		16,618
Value of share Issued in connection with acquisition of Novosteo	16,503	$ 6	16,497
Share issuance in connection with acquisition of Novosteo Inc.		5,520,000
Foreign currency translation adjustments	248			248
Unrealized gain (loss) on available for sale investments	(458)			(458)
Net loss	(51,660)				(51,660)
Ending balance at Dec. 31, 2022	$ 100,593	$ 36	$ 389,105	$ (289)	$ (288,259)
Ending balance, shares at Dec. 31, 2022		36,136,480